Trials / Conditions / Ovarian Undifferentiated Carcinoma

Ovarian Undifferentiated Carcinoma

18 registered clinical trials studyying Ovarian Undifferentiated Carcinoma.

Status	Trial	Sponsor	Phase
Active Not Recruiting	A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With NCT04092270	National Cancer Institute (NCI)	Phase 1
Terminated	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287	University of Washington	N/A
Terminated	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Re NCT02502266	National Cancer Institute (NCI)	Phase 2 / Phase 3
Active Not Recruiting	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared NCT02446600	National Cancer Institute (NCI)	Phase 3
Terminated	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cance NCT02364713	Mayo Clinic	Phase 2
Active Not Recruiting	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, NCT02101775	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Can NCT02068794	Mayo Clinic	Phase 1 / Phase 2
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Completed	EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent O NCT01489371	Gynecologic Oncology Group	Phase 1
Completed	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, NCT00888615	GOG Foundation	Phase 2
Active Not Recruiting	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712	National Cancer Institute (NCI)	Phase 3
Completed	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ov NCT01097746	M.D. Anderson Cancer Center	Phase 2
Completed	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Pa NCT00565851	National Cancer Institute (NCI)	Phase 3
Unknown	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745	GOG Foundation	Phase 3